Post-vaccine inflammation tracking: validation of a novel individualized digital inflammatory biomarker relative to serum biomarkers
Inflammatory changes play a central role in both diseases and therapeutic interventions. Wearables are a promising novel method for inflammation detection and tracking through identifying subtle, individualized physiologic changes. We evaluated a wearable-derived individualized digital biomarker, inflammatory multivariate change index (iMCI) against serum biomarkers and reactogenicity following vaccination. Sixty-one volunteers received one of four mRNA vaccines (80 total doses) and wore a torso sensor patch for 14 days starting seven days before vaccination. Changes in serum inflammatory biomarkers symptoms were tracked post-vaccine. iMCI showed moderate to strong correlation against C-reactive protein (CRP; Spearman ρ = 0.59, p < 0.01) and interferon-γ (IFN-γ; ρ = 0.56, p < 0.01), comparable to the CRP-IFN-γ correlation (ρ = 0.60, p < 0.01). Associations with systemic reactogenicity were moderate for all three measures (iMCI ρ = 0.48, p < 0.01; IFN-γ ρ = 0.34, p = 0.01; CRP ρ = 0.36, p < 0.01). These results indicate that a personalized digital biomarker offers a scalable alternative to serial blood testing for real-time inflammation tracking.
Authors
- Steven R. Steinhubl (ORCID: https://orcid.org/0000-0002-9256-7914)
- Stephan Wegerich (ORCID: https://orcid.org/0000-0002-0306-7265)
- Jadranka Sekaric
- Darpit Dave (ORCID: https://orcid.org/0000-0003-2380-4549)
- Matthew P. Ward
- Jaap Oostendorp
- Robert Paris
- Ryan Heumann
Institutions
- Purdue University West Lafayette (US)
- University of Chicago (US)
- Moderna Therapeutics (United States) (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- npj Digital Medicine
- Published
- 2026-04-22
- DOI
- https://doi.org/10.1038/s41746-026-02659-6
- Primary Topic
- Advanced Biosensing Techniques and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Moderna